Skip to main content

Table 2 Risk of prostate cancer death by the new 5-tier grade groups within treatment subgroups

From: Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings

Treatment sub-group

No. Events/Total

Competing risk regression

Unadjusted

sHR (95%CI)

p-value

Adjusted

sHRa (95%CI)

p-value

All men

259/4264

    

 Grade group I (3 + 3)

40/1780

1.0

-

1.00

 

 Grade group II (3 + 4)

52/1154

2.1 (1.4–3.2)

<0.001

2.2 (1.5–3.6)

<0.001

 Grade group III (4 + 3)

42/645

3.2 (2.1–4.9)

<0.001

2.5 (1.6–4.2)

<0.001

 Grade group IV (8)

48/399

6.1 (4.0–9.2)

<0.001

4.1 (2.6–6.7)

<0.001

 Grade group V (9–10)

77/286

16.8 (11.4–24.7)

<0.001

8.7 (5.4–14.0)

<0.001

P for trend

  

<0.001

 

<0.001

Conservative managementb

136/1033

    

 Grade group I (3 + 3)

19/518

1.0

-

1.00

 

 Grade group II (3 + 4)

25/163

4.3 (2.4–7.8)

<0.001

3.0 (1.5–5.8)

0.001

 Grade group III (4 + 3)

17/122

3.9 (2.1–7.4)

<0.001

2.2 (1.0–4.8)

0.04

 Grade group IV (8)

26/110

6.9 (3.8–12.4)

<0.001

4.1 (2.0–8.4)

<0.001

 Grade group V (9–10)

49/120

15.2 (8.9–25.8)

<0.001

8.5 (4.2–17.2)

<0.001

P for trend

  

<0.001

 

<0.001

Radical prostatectomy

22/1624

    

 Grade group I (3 + 3)

4/637

1.0

-

1.0

-

 Grade group II (3 + 4)

5/568

1.7 (0.5–6.2)

0.44

1.6 (0.4–6.1)

0.48

 Grade group III (4 + 3)

3/254

2.4 (0.5–10.5)

0.26

2.3 (0.5–10.9)

0.29

 Grade group IV (8)

6/126

9.5 (2.6–33.8)

0.001

9.5 (2.6–35.8)

0.001

 Grade group V (9–10)

4/39

29.1 (7.1–120)

<0.001

28.4 (6.4–124)

<0.001

P for trend

  

<0.001

 

<0.001

Curative radiotherapy

75/1143

    

 Grade group I (3 + 3)

15/385

1.0

-

1.00

-

 Grade group II (3 + 4)

19/314

1.8 (0.9–3.5)

0.10

1.4 (0.7–3.0)

0.37

 Grade group III (4 + 3)

19/218

2.7 (1.4–5.5)

0.003

2.3 (1.1–4.8)

0.03

 Grade group IV (8)

10/125

2.6 (1.2–5.8)

0.02

2.0 (0.8–7.8)

0.13

 Grade group V (9–10)

12/101

4.2 (2.0–9.0)

<0.001

2.8 (1.2–6.8)

0.02

P for trend

  

<0.001

 

<0.001

  1. asHR: Sub-distribution hazard ratios derived from competing risk regression adjusted for age, year of diagnosis, diagnostic PSA, clinical stage, area level SES, public /private management, treatment modality (appropriate to subgroups)
  2. bThe conservative management group consists of men who were managed through watchful waiting, active surveillance or androgen deprivation therapy alone